All stock lists
Unlock the score
Ascendis Pharma A/S (NASDAQ:ASND)
DK · Delayed Price · Currency is USD
Healthcare · Biotechnology
245.15+1.78 (+0.73%)
Market cap
$16.1B
Insider Score
Health Score
Analyst consensus
Listed since
Jan 28, 2015
Website
Insider Score
/ 100
ASND Insider Score
Ascendis Pharma A/S has a live Insider Score.
Scored on 2 qualifying trades from 1 insider in the last 90 days.
ASND analyst forecast
ASND analyst consensus
Moderate Buy12 ratings
Buy 12 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
ASND 12-month price target
$303.17+23.5% upsideaverage of 12 firms
$342.00High
$255.00Low
Best analysts covering ASND
- TD Cowen100%success rate · 4 calls
- Evercore ISI Group100%success rate · 3 calls
- Stifel100%success rate · 2 calls
- RBC Capital100%success rate · 2 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
ASND analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2026-09-25 |
| Raymond James | Outperform | $287.00 | +8.3% | Downgraded | 2026-09-15 | |
| Oppenheimer | Outperform | $312.00 | +19.9% | Reiterated | 2026-09-02 | |
| Morgan Stanley | Overweight | $273.00 | +3.8% | Reiterated | 2026-09-01 | |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-09-01 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-08-31 |
| — | Stifel | Buy | — | — | Reiterated | 2026-08-31 |
| — | Jefferies | Buy | — | — | Reiterated | 2026-08-31 |
| — | B of A Securities | Buy | — | — | Reiterated | 2026-08-31 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-08-14 |
| RBC Capital | Outperform | $290.00 | +17.4% | Reiterated | 2026-08-14 | |
| — | TD Cowen | Buy | — | — | Reiterated | 2026-08-14 |
| Jefferies | — | $333.00 | +35.2% | — | 2026-08-13 | |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-07-23 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-07-07 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2026-05-15 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-05-11 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-05-08 |
| — | B of A Securities | Buy | — | — | Reiterated | 2026-04-16 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-04-09 |
| Stifel Nicolaus | — | $332.00 | +37.5% | — | 2026-03-04 | |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-03-03 |
| Wolfe Research | — | $260.00 | +12.3% | — | 2026-03-02 | |
| Cantor Fitzgerald | — | $300.00 | +29.6% | — | 2026-03-02 | |
| Evercore ISI | — | $324.00 | +38.4% | — | 2026-03-02 | |
| Goldman Sachs | — | $255.00 | +9.2% | — | 2026-03-02 | |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2026-02-12 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-02-12 |
| Stifel Nicolaus | — | $325.00 | +49.1% | — | 2026-02-12 | |
| Morgan Stanley | — | $256.00 | +15.6% | — | 2026-02-12 | |
| — | B of A Securities | Buy | — | — | Reiterated | 2026-01-30 |
| Barclays | — | $342.00 | +43.2% | — | 2026-01-27 | |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-01-20 |
| Wells Fargo | Overweight | $330.00 | +60.3% | Reiterated | 2026-01-20 | |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-01-09 |
| — | TD Cowen | Buy | — | — | Reiterated | 2026-01-07 |
| — | Stifel | Buy | — | — | Reiterated | 2025-12-11 |
| Stifel Nicolaus | — | $256.00 | +27.1% | — | 2025-12-11 | |
| — | Wedbush | Outperform | — | — | Reiterated | 2025-11-18 |
| Cantor Fitzgerald | Overweight | $254.00 | +21.2% | Reiterated | 2025-10-13 | |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-10-09 |
| — | B of A Securities | Buy | — | — | Reiterated | 2025-09-02 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-08-19 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-08-08 |
| — | Citigroup | Buy | — | — | Reiterated | 2025-08-08 |
| — | Wedbush | Outperform | — | — | Reiterated | 2025-08-08 |
| RBC Capital | Outperform | $230.00 | +20.1% | Reiterated | 2025-08-08 | |
| — | UBS | Buy | — | — | Reiterated | 2025-08-08 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-08-08 |
| — | Stifel | Buy | — | — | Reiterated | 2025-08-08 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-07-29 |
| — | Citigroup | Buy | — | — | Reiterated | 2025-07-11 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2025-06-13 |
| — | B of A Securities | Buy | — | — | Reiterated | 2025-06-09 |
| — | B of A Securities | Buy | — | — | Reiterated | 2025-06-03 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-05-12 |
ASND earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-11 | -0.06 | -0.64 | $292.3M | $344.8M |
| 2026-05-07 | 0.19 | 0.32 | $308.9M | $284.9M |
| 2026-08-13 | 1.71 | 3.29 | $376.8M | $387.5M |
| 2026-11-11 | 0.91 | 0.00 | $412.3M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.